» BioInvent summarizes eventful Q2
» Strengthened finances and clinical development during Scandion Oncology's Q2
» CombiGene focuses on further in-licensing
» CLS – moving forward through rights issue
» Dicot's CEO on Q2
Read BioStock's newsletter for v.34 here.
Morning news
RealHeart Presenting at German blood injury conference. Read more.
CS MEDICA announces that the efficacy analysis in their clinical trial of CANNASEN CBD Psoriasis Gel (NGP-01) met all of the trial's primary and secondary efficacy endpoints. Read more.
Össur acquires Naked Prosthetics, a supplier of finger prostheses for finger and partial hand amputees. Read more.
Marking has now closed the inclusion to the HIV study of the candidate income tax 048. Read more.
NeoDynamics vd Anna Eriksrud will make a presentation and answer questions about the business in an interview in collaboration with Uddaaktier on Monday evening. Read more.
Alvotech presents ESG data for 2020 and 2021. Read more.
Madeleine Skoglund takes office as new CFO for Calmark Sweden. Read more.
Company reports:
DBP International Inhalation Sciences PolarCool Prolight Diagnostics Raysearch Laboratories Redsense Medical SpectraCure
Invitations:
Share transactions and changes in equity:
Gentian Diagnostics Lytix Biopharma Nykode Therapeutics
News since Friday lunch
Cereno Scientific reported that the first patient has started the treatment period in the phase II study with the drug candidate CS1. Read more.
AstraZeneca has presented new data showing that Farxiga significantly reduces the risk of cardiovascular death in patients with heart failure. Read more.
Camurus has presented the program for their Capital Markets and R&D Day on September 6, 2022. Read more.
Nordic Nanovector announced that they are consolidating their management team and restructuring to save resources. Read more.
ProstaLund announced that the last day for trading in BTU is today, August 29, and the first trading day for series TO2 warrants will be September 5, 2022. Read more.
Biosergen completed the third cohort study of BSG005 in its Phase I study. Read more.
Brain+ announced that their digital product for dementia, CST Therapist Companion, is ready for launch in Denmark during Q4. Read more.
TLV has decided on a subsidy for Pfizer pneumococcal vaccine Apexxxnar. Read more.
Boehringer Ingelheim Garden (empagliflozin) has received increased reimbursement for heart failure. Read more.
PCI Biotech has invited to the presentation of the Q2 report on August 31. Read more.
This morning's price development
Winner: Carbiotix 19,9%, IRRAS 16,5%, QuiaPEG Pharmaceuticals 16,4%, OncoZenge 11,4%, AdderaCare 9,7%
Förlorare: Zenicor -12,6%, ODI Pharma -12,4%, Neola Medical -11,7%, Aino Health -11,3%, Infant Bacterial Therapeutics -10,4%
Index: OMSX30 1 -929%, Healthcare -1,35%
More articles from BioStock
» Spago Nanomedical about the autumn news flow
» Continued positive sales development for Sensidose
» Continued great interest in Sprint Biosciences' program
» Things are looking up for biotech companies on the stock exchange
» Scandion Oncology is investing in breakthroughs in difficult-to-treat cancer